Douglas M. Schirle
Analyst
We reported a net loss of $210,000 or $0.01 per diluted share on net revenues of $13.8 million in the third quarter of fiscal 2014 compared to net income of $844,000 or $0.03 per diluted share on net revenues of $17.5 million in the prior year quarter ended December 31, 2012, and net income of $386,000 or $0.01 per diluted share on net revenues of $15.5 million for the preceding second quarter. Third quarter direct and indirect sales to Cisco Systems were $2.5 million or 18.4% of net revenues compared to $3.4 million or 22.2% of net revenues in the prior quarter, and $6.5 million or 37% of net revenues in the same period a year ago. Sales to Alcatel-Lucent were $2.3 million or 16.5% of net revenues during the quarter, compared to $3.2 million or 20.4% of net revenues in the prior quarter. Military/defense sales were 14.2% of shipments compared to 12.3% of shipments in the prior quarter and 11% of shipments in the comparable period a year ago. SigmaQuad sales were 39.8% of shipments compared to 42.3% in the prior quarter and 33.7% in the third quarter of fiscal 2013. Third quarter fiscal 2014 operating loss was $1.4 million compared to operating income of $241,000 in the prior quarter and operating income of $595,000 a year ago. Total operating expenses in the third fiscal quarter of 2014 were $7.5 million, up from $6.7 million in the third fiscal quarter of 2013 and up from $7.2 million in the prior quarter. Research and development expenses were $2.9 million compared to $3 million of the prior quarter and the $2.9 million in the prior year period. But selling, general and administrative expense, which included the litigation-related expenses, was up year-over-year to $4.6 million compared to $3.9 million in the fiscal quarter ended December 31, 2012, and up sequentially from $4.2 million in the prior quarter. Included in SG&A during these periods were, respectively, $2.1 million, $1.1 million and $1.7 million in litigation-related expenses. Total third quarter pretax stock-based compensation expense was $516,000 compared to $563,000 in the prior quarter, and $565,000 in the comparable quarter a year ago. Depreciation and amortization expense was $488,000 for the quarter. Our Board of Directors has authorized us to repurchase, at management's discretion, shares of our common stock. On August 20, 2013, the board increased the dollar value of shares that may be repurchased by $10 million. Under the repurchase program, we may repurchase shares from time to time on the open market or in private transactions. The specific timing and amount of the repurchases will depend on market conditions, securities laws limitations and other factors. The repurchase program may be suspended or terminated at any time without prior notice. During the quarter ended December 31, 2013, we repurchased 383,477 shares at an average cost of $6.61 per share, for a total cost of $2.5 million. To date, we have repurchased 4,014,707 shares at an average cost of $4.15 per share, for a total cost of $16.6 million. At December 31, 2013, we had $74.8 million in cash, cash equivalents and short-term investments; $34.2 million in long-term investments; $89.7 million in working capital; no debt; and stockholder's equity of $134 million. Accounts payable at December 31, 2013, was $3 million compared to $3.7 million at September 30, 2013. Net inventory was $10 million at December 31, 2013, down from $11.2 million at September 30, 2013. Inventory turns at December 31, 2013, were 2.9x, unchanged from September 30, 2013. Looking forward to the fourth quarter, we currently expect net revenues to be in the range of $12.5 million to $13.5 million, with gross margin of approximately 38% to 40%. We also expect that ongoing legal expenses related to the patent litigation and antitrust litigation will continue to affect our operating income and our bottom line. These expenses are difficult to forecast, but we currently estimate that they will be approximately $1.5 million in the fourth quarter. Operating expenses in total are expected to be approximately $8.5 million and will include approximately $1.5 million in total related to R&D mask sets, one for a 288 MB device, which will be our first 40-nanometer tape-out, and the second for the next-generation -- for our next-generation LLDRAM device, in addition to the estimated litigation-related expenses of $1.5 million. Operator, at this time, we'll open the call for Q&A.